Wells Fargo’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-78,771
| Closed | -$1.42M | – | 7330 |
|
|
2020
Q2 | $1.42M | Sell |
78,771
-298,423
| -79% | -$4.15M | ﹤0.01% | 3546 |
|
|
2020
Q1 | $2.69M | Buy |
377,194
+101,753
| +37% | +$1.27M | ﹤0.01% | 2757 |
|
|
2019
Q4 | $6.58M | Sell |
275,441
-9,469
| -3% | -$261K | ﹤0.01% | 2326 |
|
|
2019
Q3 | $7.64M | Buy |
284,910
+55,880
| +24% | +$1.57M | ﹤0.01% | 2166 |
|
|
2019
Q2 | $6.21M | Sell |
229,030
-5,963
| -3% | -$187K | ﹤0.01% | 2374 |
|
|
2019
Q1 | $8.15M | Buy |
234,993
+151,454
| +181% | +$4.37M | ﹤0.01% | 2100 |
|
|
2018
Q4 | $1.63M | Buy |
83,539
+8,494
| +11% | +$175K | ﹤0.01% | 3446 |
|
|
2018
Q3 | $2M | Sell |
75,045
-366,648
| -83% | -$12M | ﹤0.01% | 3410 |
|
|
2018
Q2 | $16.7M | Buy |
441,693
+385,547
| +687% | +$14.7M | ﹤0.01% | 1634 |
|
|
2018
Q1 | $1.83M | Sell |
56,146
-630,670
| -92% | -$27.7M | ﹤0.01% | 3449 |
|
|
2017
Q4 | $33.4M | Buy |
686,816
+640,023
| +1,368% | +$32.4M | 0.01% | 1125 |
|
|
2017
Q3 | $2.53M | Buy |
46,793
+5,010
| +12% | +$294K | ﹤0.01% | 3123 |
|
|
2017
Q2 | $2.35M | Sell |
41,783
-15,602
| -27% | -$625K | ﹤0.01% | 3101 |
|
|
2017
Q1 | $2.25M | Sell |
57,385
-43,170
| -43% | -$1.37M | ﹤0.01% | 3105 |
|
|
2016
Q4 | $2.26M | Buy |
100,555
+66,995
| +200% | +$1.31M | ﹤0.01% | 3065 |
|
|
2016
Q3 | $763K | Sell |
33,560
-385,333
| -92% | -$9.04M | ﹤0.01% | 3686 |
|
|
2016
Q2 | $9.88M | Buy |
418,893
+62,965
| +18% | +$1.55M | ﹤0.01% | 1846 |
|
|
2016
Q1 | $7.26M | Buy |
355,928
+62,007
| +21% | +$1.97M | ﹤0.01% | 2037 |
|
|
2015
Q4 | $15.1M | Buy |
293,921
+10,544
| +4% | +$511K | 0.01% | 1515 |
|
|
2015
Q3 | $12.1M | Sell |
283,377
-4,177
| -1% | -$202K | 0.01% | 1669 |
|
|
2015
Q2 | $13.1M | Buy |
287,554
+43,102
| +18% | +$1.73M | 0.01% | 1694 |
|
|
2015
Q1 | $9.28M | Sell |
244,452
-46,204
| -16% | -$1.59M | ﹤0.01% | 1941 |
|
|
2014
Q4 | $8.23M | Buy |
290,656
+45,338
| +18% | +$1.26M | ﹤0.01% | 1963 |
|
|
2014
Q3 | $6.2M | Buy |
245,318
+21,636
| +10% | +$570K | ﹤0.01% | 2138 |
|
|
2014
Q2 | $6.53M | Sell |
223,682
-4,403
| -2% | -$107K | ﹤0.01% | 2140 |
|
|
2014
Q1 | $5.91M | Buy |
228,085
+35,394
| +18% | +$945K | ﹤0.01% | 2213 |
|
|
2013
Q4 | $4.96M | Buy |
192,691
+110,808
| +135% | +$2.69M | ﹤0.01% | 2273 |
|
|
2013
Q3 | $2.19M | Sell |
81,883
-11,121
| -12% | -$265K | ﹤0.01% | 2826 |
|
|
2013
Q2 | $2.29M | Buy |
+93,004
| New | +$1.85M | ﹤0.01% | 2720 |
|
Wells Fargo's PTLA Position: Q3 2020 in Review
Wells Fargo sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 78,771 shares — an estimated $1.42M sold.
Wells Fargo first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $33.4M in Q4 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Wells Fargo reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Wells Fargo sold 78,771 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1.42M.
- Wells Fargo first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Wells Fargo's Portola Pharmaceuticals, Inc. position peaked at $33.4M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Wells Fargo's 13F filing for Q3 2020, filed 5 Nov 2020.